ERBB2 and cancer: Indeed, our research findings have demonstrated that cancer cells from NSCLC patients harboring a FHITlow/pHER2high phenotype exhibited greater responsiveness to anti-HER2 targeted therapies (such as trastuzumab and tucatinib) compared to other phenotypes [31].